Tomi Environmental’s Earnings Call Balances Promise and Risk

Tomi Environmental Solutions, Inc. ((TOMZ)) has held its Q4 earnings call. Read on for the main highlights of the call.

Tomi Environmental Solutions’ latest earnings call struck a cautiously optimistic tone as management balanced clear operational progress with stark financial constraints. Executives pointed to growing recurring revenue, margin expansion, and regulatory wins, yet acknowledged a steep revenue drop in 2025, thin cash reserves, and ongoing losses that keep liquidity and execution risk front and center.

Commercial and Integration Milestones

Tomi reported its first commercial SIS installation in June 2025 and ended the year with four fully operational SIS enclosures, marking tangible traction for its integration strategy. A $500,000 December contract from a global biopharma player for pass-through fill boxes and a combined $36 million opportunity book for integration and SteraMist iHP projects underscore the potential scale if the pipeline converts.

Strategic OEM and Distribution Partnerships

Partnerships with OEMs such as PBSC, ESCO, and Steelco are embedding SteraMist iHP into clean room enclosures and biosafety cabinets, with one PBSC pass-through project outperforming cycle-time expectations and a follow-on project already underway. International distributors, including ARES Scientific and U.K.-based TCA, are helping secure wins at universities and regional customers, broadening the company’s geographic and sector reach.

Recurring Revenue Traction and Backlog Growth

Management emphasized progress toward a more recurring model, noting that TOMI Support Services backlog grew 16% and BIT Solution backlog rose 24% in Q1 2026 versus a year earlier. Growing open BIT Solution orders and the shift to recurring open-order arrangements are central to the strategy of smoothing revenue volatility and building steadier cash flows.

Q1 2026 Revenue Momentum vs Prior Year

While full-year 2025 revenue declined, early 2026 trends are more encouraging, with management stating that Q1 2026 revenue exceeded Q1 2025. Solution sales climbed about 43.7% to $429,413, support services surged roughly 245.8% to $253,390, and iHP service invoices plus open orders rose about 66.1% to $729,440, signaling healthier demand across the portfolio.

Margin Improvement and Cost Discipline

Despite top-line pressure, Tomi expanded gross margin to approximately 55% in 2025 from 46% in 2024, a nine-point gain that reflects better mix and operational efficiency. Total operating expenses fell about 10% year over year, showing management’s focus on tightening costs even as it invests selectively in growth initiatives.

Improved Losses and Cash Flow Usage

Net loss narrowed to $3.7 million, or $0.19 per share, in 2025 from $4.5 million, or $0.22 per share, in 2024, an improvement of roughly 17.8% as margins improved and expenses were controlled. Operating cash usage also improved, with cash used in operations declining to $1.2 million from $1.4 million, suggesting incremental progress toward more sustainable cash dynamics.

Regulatory and Market Approvals Supporting New Verticals

A late-2025 FDA approval of hydrogen peroxide as a direct food additive is opening new food safety avenues, including engagements with large multinationals in dairy and nutrition. Additional regulatory recognition in the U.K. and the Netherlands, together with ongoing work on key U.S. labels and approvals, is gradually widening the addressable market, though some approvals are still pending.

Notable Customer Wins and Use-Cases

Tomi highlighted several marquee wins, including adoption of SteraMist iHP by a cell and gene therapy manufacturer for a commercial-scale pharma facility and selection by NASA’s Johnson Space Center for a biosecurity operation. An eye‑health customer expanded to two active facilities with multiple machines per site and is trialing a third location, while the Algafeed collaboration extends the platform into agricultural and food-related applications.

Intellectual Property, Reach and Industry Recognition

The company underscored its technology moat, noting more than 30 utility and design patents extending to 2038 and deployments in over 40 countries. Recognition as Disinfection Decontamination Products Company of the Year and compliance across multiple vendor management platforms reinforce its credibility with institutional buyers in regulated environments.

Financing Tools Put in Place

To shore up liquidity, Tomi raised $535,000 through a convertible note in 2025 and arranged a $20 million equity line, drawing about $94,000 so far, while also putting in place a sizable shelf registration. Management has also engaged a financial advisor to explore additional capital options, signaling an active approach to funding future growth and working capital needs.

Decline in Annual Revenue

Against these operational wins, full-year revenue fell sharply to $5.6 million in 2025 from $7.7 million in 2024, a drop of roughly 27.3%. Management attributed the decline largely to the timing of customer equipment purchases and deferred capital spending rather than lost deals, but the shortfall underscores the company’s sensitivity to CapEx cycles.

Weak Year-End Liquidity and Cash Position

The company closed 2025 with just about $88,000 in cash and around $1 million in working capital, levels that raise clear near-term liquidity concerns for investors. These constraints help explain the flurry of financing actions and heighten the importance of converting backlog and pipeline into cash-generating sales on a timely basis.

Continued Net Loss and Reliance on External Financing

Although losses narrowed, Tomi remains firmly unprofitable with a $3.7 million net loss in 2025, and management acknowledged ongoing reliance on external capital sources. The business model’s transition toward recurring revenue is still underway, meaning equity lines, notes, and other financings remain critical to support operations and growth projects.

Customer Deferrals and Macroeconomic Headwinds

Executives pointed to macro and political uncertainties, including tariffs and global conflicts, as drivers of customer caution and CapEx deferrals. One cited example involved a large university pushing major equipment spending to late 2026, illustrating how external factors can delay the realization of even well-qualified pipeline opportunities.

Partial Conversion of Pipeline to Recognized Revenue

From a previously announced $3 million integration pipeline in late 2025, only about $800,000 has been recognized so far, leaving several projects awaiting final approvals and execution. This gap between announced pipeline and realized revenue highlights timing and execution risk, which could weigh on results if delays persist or deals fail to close.

Scaling Constraints and Need for Capital

Management acknowledged that with a team of roughly 20 employees, the company would need more capital and headcount to scale production and service capacity for large new orders. While this lean structure helps control costs, it also limits how quickly Tomi can ramp if multiple sizable integration or OEM projects move forward at once.

Regulatory Work Still Required in Key Markets

Several important regulatory pathways remain unfinished, including certain environmental and product labels and industry-specific approvals that are vital for markets such as cannabis and biosafety cabinets. Until these are secured, revenue growth in these verticals will be constrained, making regulatory execution a critical factor in the growth story.

Stock Price Decline and Market Valuation Pressure

Management noted that the share price has fallen significantly from prior highs, with the stock trading well below a dollar at year-end and at the time of the call. This market pressure reflects investor concerns over near-term financial health and dilution risk, even as management argues that technology progress and partnerships are not yet fully appreciated.

Outlook and Forward Guidance

Looking to 2026, Tomi guided to roughly $12 million in revenue, about double 2025 levels, supported by a $16 million integration pipeline and $20 million in SteraMist iHP opportunities. Management expects around $3 million of sales from five named customers and roughly $6 million when including steady iHP deployment services, while noting that operating expenses should grow more slowly than revenue as backlog and recurring orders convert.

Tomi’s earnings call presented a story of promising technology and early commercial traction weighed down by tight liquidity and lumpy revenue. For investors, the key debate is whether the expanding pipeline, regulatory tailwinds, and recurring revenue gains can materialize fast enough to offset funding needs and macro-related delays, making execution over the next few quarters crucial for the stock’s trajectory.